Allergan reports nearly 24% increase in second quarter product sales

IRVINE, Calif. — Allergan had $972.8 million in total product net sales in the second quarter, a 23.6% increase compared with the second quarter 2006, the company announced in a press release.

In the second quarter, total specialty pharmaceutical net sales increased 16.2% and total core medical device net sales increased 53.6%, compared with the second quarter of last year.

Specifically, compared with the second quarter 2006, eye care pharmaceutical sales increased 13.8% to $431.4 million. Alphagan P, Alphagan and Combigan product sales increased 10.3% to $77.4 million, Lumigan product sales increased 15.7% to $94.5 million and Restasis sales increased 17.8% to $77.3 million.

For the first half of 2007, eye care pharmaceutical sales increased 12.6% over the first half of 2006 to total $834.4 million. Also compared with the first half of last year, Alphagan P, Alphagan and Combigan product sales increased 9.8% to $155 million, Lumigan product sales increased 18.7% to $183.5 million and Restasis sales increased 18.2% to $155.7 million, according to the release.

For the full year, Allergan expects total product net sales between $3.66 billion and $3.76 billion, including between $2.99 billion and $3.02 billion in total specialty pharmaceuticals net sales.

The company's board of directors also declared a second quarter dividend of $0.05 per share, which is payable on Sept. 7 to stockholders on record as of Aug. 17, the release said.